It’s already working with partners like Stanford University, Baylor College of Medicine and Google, but DNAnexus said today it’s restocked with $15 million from investors to keep pushing adoption of its enterprise platform for DNA sequencing data.
Claremont Creek Ventures, Google Ventures, TPG Biotech and First Round Capital funded the company’s Series C, which CEO Richard Daly said in a statement would help it accelerate commercialization and better support the labs already using its platform.
DNAnexus offers cloud-based solutions that sequencing facilities, diagnostic testing labs and research centers use to manage, access and analyze sequencing data and collaborate with other scientists.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s working with Amazon and Baylor to provide a cloud-based infrastructure for the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, an initiative to study how human genetics relates to heart disease and aging. It’s also working with Stanford on the 1000 Genomes Project, which developed a large catalog of human genetic variation.
The Mountain View, Calif., company said it’s “experiencing rapid customer adoption,” but it’s also got plenty of competition from others like Knome and Spiral Genetics.
Google Ventures joined in the company’s investor syndicate with its $15 million Series B in 2011. “The next wave of insights in genetics comes from multi-institutional collaborative efforts producing huge amounts of data,” general partner Krishna Yeshwant said in a statement. “DNAnexus has created a system where large enterprises, laboratories and individuals can collaborate more efficiently using modern cloud technologies.”
[Photo credit: Freedigitalphotos user dream designs]
